We are excited to announce the granting of Orphan Drug Designation for MG-S-2525, our MAP3K19 inhibitor for Idiopathic Pulmonary Fibrosis, by the FDA. Congratulations to our team and partners at SMA Therapeutics, Inc. for achieving this significant milestone and we look forward to the advancement of this important therapeutic and making a significant clinical impact in IPF and COPD. For more information on the clinical study program for MG-S-2525, please follow this link (http://metagone.com.tw/eng/p3_news_detail5.php).